These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35905933)

  • 1. Enhanced half-life and antitumor activity of interleukin-15 through genetic fusion of a serum albumin-specific protein binder.
    Kim D; Park JH; Kim TY; Kim DG; Byun JH; Kim HS
    Int J Pharm; 2022 Sep; 625():122059. PubMed ID: 35905933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
    Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
    Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy.
    Cini JK; Dexter S; Rezac DJ; McAndrew SJ; Hedou G; Brody R; Eraslan RN; Kenney RT; Mohan P
    Front Immunol; 2023; 14():1326927. PubMed ID: 38250068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
    Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
    Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
    Jiang W; Zhang C; Tian Z; Zhang J
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.
    Tosic V; Thomas DL; Kranz DM; Liu J; McFadden G; Shisler JL; MacNeill AL; Roy EJ
    PLoS One; 2014; 9(10):e109801. PubMed ID: 25329832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 15 and CD4⁺ T cells cooperate to promote small intestinal enteropathy in response to dietary antigen.
    Korneychuk N; Ramiro-Puig E; Ettersperger J; Schulthess J; Montcuquet N; Kiyono H; Meresse B; Cerf-Bensussan N
    Gastroenterology; 2014 Apr; 146(4):1017-27. PubMed ID: 24361466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
    Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
    Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
    Ye JF; Qi WX; Liu MY; Li Y
    Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
    Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice.
    Song Y; Liu Y; Hu R; Su M; Rood D; Lai L
    Mol Cancer Ther; 2016 Oct; 15(10):2413-2421. PubMed ID: 27474151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
    Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
    Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy.
    Xu X; Sun Q; Mei Y; Liu Y; Zhao L
    Cancer Sci; 2018 Feb; 109(2):279-288. PubMed ID: 29224228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a γc Receptor Antagonist That Prevents Reprogramming of Human Tissue-resident Cytotoxic T Cells by IL15 and IL21.
    Ciszewski C; Discepolo V; Pacis A; Doerr N; Tastet O; Mayassi T; Maglio M; Basheer A; Al-Mawsawi LQ; Green PHR; Auricchio R; Troncone R; Waldmann TA; Azimi N; Tagaya Y; Barreiro LB; Jabri B
    Gastroenterology; 2020 Feb; 158(3):625-637.e13. PubMed ID: 31622625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma.
    Hsu FT; Liu YC; Tsai CL; Yueh PF; Chang CH; Lan KL
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human umbilical cord blood-derived mesenchymal stem cells producing IL15 eradicate established pancreatic tumor in syngeneic mice.
    Jing W; Chen Y; Lu L; Hu X; Shao C; Zhang Y; Zhou X; Zhou Y; Wu L; Liu R; Fan K; Jin G
    Mol Cancer Ther; 2014 Aug; 13(8):2127-37. PubMed ID: 24928851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent manner.
    Polansky JK; Bahri R; Divivier M; Duitman EH; Vock C; Goyeneche-Patino DA; Orinska Z; Bulfone-Paus S
    Sci Rep; 2016 Jan; 6():19699. PubMed ID: 26822794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
    Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
    Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel strategy to produce high level and high purity of bioactive IL15 fusion proteins from mammalian cells.
    Huang H; Luo Y; Baradei H; Liu S; Haenssen KK; Sanglikar S; Kumar S; Cini J
    Protein Expr Purif; 2018 Aug; 148():30-39. PubMed ID: 29596991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.